Fujita M, Fujita F, Uchida J, Takeda S, Yamada Y, Taguchi T
Dept. of Surgery, Research Institute for Microbial Disease, Osaka University.
Gan To Kagaku Ryoho. 1990 Apr;17(4 Pt 1):627-32.
We studied the relationship between antitumor efficacy of UFT, which is a most widely used drug among fluorinated pyrimidines recently, and its effect on the content and the inhibition rate of thymidylate synthase (TS) in 15 human tumor xenografts derived from stomach, colon, breast and pancreatic cancer patients. There was a linear relationship between the content of TS and tumor mass doubling time (MDT). It may be shown that TS content reflects the growth rate of tumor cells. It should be stressed that tumor growth inhibition rate (TGIR), induced by UFT, correlated well with the inhibition of TS (TSI), particularly in the stomach and breast cancer. These results demonstrate that the measurement of inhibition rate of TS is important for the prediction and evaluation of clinical efficacy of UFT.
我们研究了优福定(UFT)(最近在氟嘧啶类药物中使用最为广泛)的抗肿瘤疗效与其对源自胃癌、结肠癌、乳腺癌和胰腺癌患者的15种人肿瘤异种移植瘤中胸苷酸合成酶(TS)含量及抑制率的影响之间的关系。TS含量与肿瘤质量倍增时间(MDT)之间存在线性关系。可以表明TS含量反映了肿瘤细胞的生长速率。应当强调的是,UFT诱导的肿瘤生长抑制率(TGIR)与TS抑制(TSI)密切相关,尤其是在胃癌和乳腺癌中。这些结果表明,TS抑制率的测定对于预测和评估UFT的临床疗效很重要。